A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Oral Doses of SUL-238 in Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 83
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events as Measured by NCI-CTCAE criteria
研究概览
简要总结
The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).
详细描述
This double-blind placebo-controlled study will be completed in 4 parts.
Part 1 will be single ascending dose in which 6 different oral doses (50 mg, 100 mg, 250 mg, 500 mg, 1000 mg and 2000 mg) will be administered to healthy adult male subjects. Each dosing group, including dose escalations, will be performed as described below:
Dose escalation will be performed until suspected adverse events (AEs) are observed. AEs will be evaluated by the blinded investigator, based on clinical signs detailed in the MedDRA criteria. At each dose level, 2 subjects will be administered SUL-238, whereas 1 subject will be administered the placebo. Escalation to the next higher dose level may occur only if no treatment-emergent AEs are observed in the 2 subjects that received SUL-238. If 1 out of 2 subjects experiences a suspected AE, 5 new subjects will be enrolled at the same dose level (4 subjects will receive one SUL-238 tablet and 1 subject will receive one placebo tablet). If no further suspected AEs occur, escalation to the next higher dose level will be performed. If any additional suspected AE is noted, dose escalation is stopped, and the previous dose level is considered the maximum tolerated dose (MTD). If suspected AE are observed in 2 subjects, dose escalation will be stopped and 5 new subjects (4 subjects will receive one SUL-238 tablet and 1 subject will receive one placebo tablet) will be enrolled at the next lower dose level. If no further suspected AE are observed, this dose level is considered the MTD.
Part 2 of the study will be single dose pharmacokinetics study in which 1 dose level below that with suspected AEs will be administered to 10 healthy adult male or female subjects (aged ≥40 years). Five male subjects and 5 female subjects will receive SUL-238. After obtaining the initial PK results from Part 1, at least 3 volunteers who accept to be tapped for Cerebrospinal Fluid (CSF) collection will provide one CSF sample on Day 1, at the time point of 1 hour after reaching Cmax during Part 2 of the study.
Part 2B will be a randomized, single-dose, two-treatment, two-period, crossover study. A total of twenty (20) healthy adults (10 male and 10 female volunteers, aged ≥40 years) will be included. The volunteers will be randomized equally into two treatment groups (each group will have 5 male and 5 female volunteers) in the first period: fasted versus high-fat-fed. All volunteers will receive a single dose of 2000 mg SUL-238 either in a fasted state (at least 10 hours) or after consuming a standardized high-fat meal (30 minutes before the study drug). In the second period, which will be conducted 14 days after the first period (washout period), a crossover will be implemented: volunteers who received SUL-238 in a fasted state in the first period will receive 2000 mg SUL-238 after a high-fat meal in the second period, and vice versa. A high-fat meal will have a total of 800-1000 calories, with ≥50% (500-600 calories) coming from fat. At least three volunteers in each group who accept to be tapped for CSF collection will provide one CSF sample on Day 1, at the time point of 1 hour after reaching Cmax during Part 2B of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by the Investigator, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and cardiac monitoring.
- •Men and women aged≥40 years at Screening.
- •Subject must understand the nature of the study and provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures.
- •Able to complete all study related testing and evaluations.
- •Women and men of child-bearing potential with partners of child-bearing potential must agree to use highly effective contraception. For male subjects, contraception should continue for 90 days after the last dose of investigational medicinal product (IMP, one spermatic cycle).
- •Women of non-childbearing potential must be post-menopausal (the last menstrual period was at least 12 months ago, and follicle-stimulating hormone [FSH] at Screening confirms post-menopausal status), or have no uterus, ovaries, or fallopian tubes (or have their fallopian tubes tied). All women must have a negative pregnancy test result before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
- •Body weight > 50 kg for men and > 50 kg for women and Body Mass Index (BMI) within the range 18.5-30.0 kg/m2, inclusive.
- •Subject must be, in the opinion of the Investigator, able to participate in all scheduled evaluations, likely to complete all required tests, and likely to be compliant.
排除标准
- •A positive urine drug screen/alcohol breath test at Screening or Day -
- •Any history of intellectual disability or psychiatric disorders, including substance use disorders, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, except a history of mild depression/anxiety that has been resolved for at least the past 12 months.
- •A positive Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) antibody test at Screening.
- •Alanine aminotransferase or aspartate aminotransferase levels greater than 1.5 times the upper limit of normal (ULN) at Screening or between Screening and first dose administration.
- •History of regular alcohol consumption within the last 12 months, defined as an average weekly intake of >21 alcoholic drinks/week for men or >14 alcoholic drinks/week for women.
- •Regularly consumed (e.g., more days than not) excessive quantities of xanthine-containing beverages (e.g., more than five cups of coffee or the equivalent per day) within 30 days prior to Day -
- •Received or used an investigational product (including placebo) or device within the following time period prior to Day -1 in the current study: 90 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Use of prescription or non-prescription drugs, vitamins, herbal, and dietary supplements within 7 days (or 28 days if the drug is a potential hepatic enzyme inducer) or 5 half-lives (whichever is longer) prior to Day -
- •History of clinically significant sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
- •A positive serum pregnancy test or lactation.
- •A history or presence of any disease, condition, or surgery likely to affect drug absorption, distribution, metabolism, or excretion. Subjects with a history of cholecystectomy should be excluded.
- •A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, or neurologic abnormality.
- •Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, in the judgement of the Investigator or Medical Monitor, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.
- •A clinically significant vital signs abnormality at Screening or Day -1 This includes, but is not limited to, the following, in the sitting position (3 measurements, each 5 minutes apart): (a) systolic blood pressure < 90 or >140 mmHg, (b) diastolic blood pressure < 50 or > 95 mmHg, or (c) heart rate < 45 or > 100 beats per minute.
- •Subjects who have previously been enrolled in this study.
- •The subject is, in the opinion of the Investigator or Medical Monitor, unlikely to comply with the protocol or is unsuitable for any reason, e.g., known issues with ability to swallow tablets.
研究组 & 干预措施
Single dose Placebo (food effect)
PART 2B: Single oral dose of placebo
干预措施: Single dose placebo (food effect) (Drug)
Single dose SUL-238
PART 1: Single ascending oral doses of SUL-238 (50 mg, 100 mg, 250 mg, 500 mg, 1000 mg and 2000 mg)
干预措施: Single ascending doses SUL-238 (Drug)
Single dose placebo
PART 1: Single oral dose of placebo
干预措施: Single dose Placebo (Drug)
Single dose pharmacokinetics of SUL-238
PART 2: Single oral dose of SUL-238 (at maximum tolerated dose)
干预措施: Single dose SUL-238 (Drug)
Multiple doses SUL-238
PART 3: Multiple ascending oral doses of SUL-238 (at maximum tolerated dose and 1 dose level lower than MTD)
干预措施: Multiple ascending doses SUL-238 (Drug)
Multiple doses placebo
PART 3: Multiple oral doses of placebo
干预措施: Multiple doses Placebo (Drug)
Single dose pharmacokinetics of SUL-238 (food effect)
PART 2B: 2000 mg single oral dose of SUL-238
干预措施: 2000 mg SUL-238 single dose for pharmacokinetics (food effect) (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events as Measured by NCI-CTCAE criteria
时间窗: Up to day 29
The safety and tolerability of SUL-238 will be assessed by documenting adverse events occurring after single dose administration on Day 1 in Part 1, Part 2 and Part 2B until Day 29. After once daily continuous dosing of SUL-238 for 14 Days in Part 3, the safety and tolerability of SUL-238 will be assessed by documenting adverse events occurring after during multiple dose administrations until Day 29. There will be no dosing between Day 15 and 29 in Part 3.
Incidence of Treatment-Emergent Adverse Events as Measured by Clinical Laboratory Measurements According to Established Clinical Normal Ranges
时间窗: Up to day 29
Clinical laboratory tests include hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase. * Change from baseline (pre-dose sample) at 24 hours (Day 2) and Days 3, 4, 8, 15 and 29 post-dose of SUL-238 (Part 1, Part 2). * Change from baseline (pre-dose sample) at 24 hours (Day 2) and Days 3, 4, 8, and from Day 14 (pre-second dose baseline), at 24 hours post-second dose (Day 16), and Days 17, 18, 22 and 29 post-first dose of SUL-238 (Part 2B). * Change from baseline (pre-dose sample) at 24 hours (Day 2) and at Days 3, 4, 8, 14 (1 hour post-last dose), 15 (24 hours post-last dose), 16, 17, 22 and 29 post-first dose SUL-238 for Part 3. * Blood and urine samples will be taken after administration of SUL-238 and values will be compared to baseline and established normal ranges to determine how SUL-238 administration impacts normal body function.
Incidence of Treatment-Emergent Adverse Events as Measured by ECG
时间窗: Up to day 29
* As compared to baseline (an ECG taken at 60 minutes pre-dose); ECG evaluations will be performed at 30 minutes, 1 hour, 12 hours post-dose and Days 2 (24 hours), 3, 4, 8, 15 and 29 post-dose of SUL-238 occurring after single dose administration (Part 1 and Part 2). * As compared to baseline (an ECG taken at 60 minutes pre-dose); ECG evaluations will be performed at 30 minutes, 1 hour, 12 hours post-first dose and Days 2 (24 hours), 3, 4, as well as Days 15 (at 60 minutes pre-second dose and at 30 minutes, 1 hour, 12 hours post-second dose), 16 (24 hours post-second dose), 17, 18, 22, and 29 (Part 2B). * As compared to baseline (an ECG taken at 60 minutes pre-dose); ECG evaluations will be performed at 30 minutes, 1 hour, 12 hours post-dose and Days 2 (24 hours), 3, 4, 8, 14 (1-hour post-last dose), 15, 16, 17, 22, and 29 post-dose SUL-238 for Part 3.
Incidence of Treatment-Emergent Adverse Events as Measured by physical examination and vital signs
时间窗: Up to day 29
Vital signs include blood pressure, heart rate and oral temperature. Change from baseline at every time points defined for Part 1, Part 2, Part 2B, and Part 3 until Day 29 post-first dose of SUL-238.
Incidence of Treatment-Emergent Adverse Events as Measured by central nervous system (CNS) and autonomic nervous system (ANS) examination.
时间窗: Up to day 29
After each dose of SUL-238 through completion of dosing, up to Day 29 in Part 1, Part 2, Part 2B, and Part 3, at all timepoints defined for the evaluation of adverse events, CNS and ANS examinations will be performed, and outcomes will be documented. CNS examinations should include evaluation of mental status, cranial and peripheral nerves, muscle strength, gait and coordination, sensations and reflexes. For the evaluation of ANS, the presence of postural hypotension, heart rate changes, pupil reflex change to light and signs and symptoms of decreased or absent sweating should be checked.
次要结局
- PK parameter: Maximum drug concentration in plasma (Cmax) of SUL-238 after a single ascending dose (Part 1 and Part 2).(Part 1 and Part 2: Up to day 4)
- Food effect on PK parameter: Maximum drug concentration in plasma (Cmax) of SUL-238 after a single dose (Part 2B).(Up to day 18)
- PK parameter: Maximum drug concentration in plasma (Cmax) of SUL-238 after multiple ascending doses (Part 3).(Part 3: Up to day 17)
- PK parameter: Area under the concentration-time curve in plasma (AUC) of SUL-238 after single ascending dose (Part 1 and Part 2).(Part 1 and Part 2: Up to day 4)
- Food effect on PK parameter: Area under the concentration-time curve in plasma (AUC) of SUL-238 after single dose in each period (Part 2B).(Up to day 18)
- The cerebrospinal fluid (CSF) levels of SUL-238(Part 2 and Part 2B: Day 1 and Part 3: Day 8)
- PK parameter: Area under the concentration-time curve in plasma (AUC) of SUL-238 after multiple ascending doses (Part 3).(Part 3: Up to day 17)
- Percentage of drug excreted in feces after multiple ascending doses of SUL-238.(Part 3: Up to day 29)
- Renal clearance and percentage of drug excreted in urine after single and multiple ascending doses of SUL-238.(Part 1 and Part 2: Up to day 2, Part 2B: Up to day 16 and Part 3: Up to day 15)